Cure8 news brief
Many people with IBD in remission still have IBS-like symptoms. These recommendations help avoid unnecessary escalation of immunosuppressive or biologic therapy by requiring objective evidence of remission and offering symptom-directed treatments that can improve quality of life.
Clinicians treating IBD, adult patients with IBD who have persistent abdominal pain or altered bowel habits despite apparent remission, and care teams offering dietary or behavioral therapies.
The guidance emphasizes combining Rome clinical criteria with objective tests to exclude active inflammation before changing IBD therapy.
Noninflammatory symptom-directed treatments — dietary strategies (short-term low-FODMAP), laxatives/antidiarrheals for bowel habit, neuromodulators for pain, and GI-focused CBT — are recommended as appropriate components of care. Psyllium is suggested when strictures are not present.
Clinicians are advised to integrate brain–gut therapies earlier rather than reserving them only for refractory cases. This is a consensus document based on systematic reviews and RAND/UCLA methodology rather than a single randomized trial, intended to standardize terminology and guide both clinical care and research.
This is a consensus guideline developed from systematic reviews and expert panel ratings (RAND/UCLA) rather than primary randomized trial evidence for every recommendation. Thresholds (eg, fecal calprotectin <150 µg/g) and some treatment suggestions are consensus-based; individual care should be personalized and discussed with a provider.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A simple blood test (CRP) that's already used in IBD care might help predict which Crohn's patients with C. difficile coinfection are more likely to need intestinal surgery, enabling earlier attention or monitoring.
Distinguishing Crohn’s disease from gastrointestinal tuberculosis is difficult in TB-endemic areas and can delay correct treatment. Persistent ileocolonic inflammation after full antituberculosis therapy plus negative TB...
Updated treat-to-target recommendations affect how inflammation and symptoms are monitored and when treatments should be changed. Clear targets and timing help patients and clinicians make consistent, evidence-informed...
